| Dr Melissa Iglesias, DO | |
|
11641 Kew Gardens Ave Ste 209, Palm Beach Gardens, FL 33410-2846 | |
| (561) 331-3833 | |
| (561) 331-3893 |
| Full Name | Dr Melissa Iglesias |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 21 Years |
| Location | 11641 Kew Gardens Ave Ste 209, Palm Beach Gardens, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225112634 | NPI | - | NPPES |
| 102436007 | Medicaid | PA | |
| 012387200 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0107X | Ophthalmology - Retina Specialist | OS12688 (Florida) | Secondary |
| 207W00000X | Ophthalmology | OS12688 (Florida) | Primary |
| Entity Name | Deval D Joshi Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053760686 PECOS PAC ID: 5991091670 Enrollment ID: O20160906002036 |
News Archive
New COVID-19 test evaluates herd immunity and vaccine efficacy with high accuracy.
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
AtheroMed, a developer of innovative technologies for treating peripheral artery disease, announced that it has completed patient enrollment in the EASE clinical study. The EASE study results will be presented by Dr. Stephen Williams, Director, Vascular Medicine Center at Johns Hopkins University, during a Late Breaking Clinical Trials Session on Wednesday, October 9th, at the Vascular Interventional Advances conference in Las Vegas.
Children who are exposed to polychlorinated biphenyls (PCBs), which were commonly used in a range of industrial products, could be at risk of an increase in asthma symptoms, according to new research.
› Verified 3 days ago
| Entity Name | Iglesias Eye Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679141238 PECOS PAC ID: 1153723598 Enrollment ID: O20210708000951 |
News Archive
New COVID-19 test evaluates herd immunity and vaccine efficacy with high accuracy.
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
AtheroMed, a developer of innovative technologies for treating peripheral artery disease, announced that it has completed patient enrollment in the EASE clinical study. The EASE study results will be presented by Dr. Stephen Williams, Director, Vascular Medicine Center at Johns Hopkins University, during a Late Breaking Clinical Trials Session on Wednesday, October 9th, at the Vascular Interventional Advances conference in Las Vegas.
Children who are exposed to polychlorinated biphenyls (PCBs), which were commonly used in a range of industrial products, could be at risk of an increase in asthma symptoms, according to new research.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Melissa Iglesias, DO 11641 Kew Gardens Ave Ste 209, Palm Beach Gardens, FL 33410-2846 Ph: (561) 331-3833 | Dr Melissa Iglesias, DO 11641 Kew Gardens Ave Ste 209, Palm Beach Gardens, FL 33410-2846 Ph: (561) 331-3833 |
News Archive
New COVID-19 test evaluates herd immunity and vaccine efficacy with high accuracy.
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the U.S. Food and Drug Administration has approved its Investigational New Drug Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
Tolerx, Inc., a biopharmaceutical company developing novel therapies by modulating T cell activity, and the Cancer Vaccine Acceleration Fund (CVAF) a nonprofit program of the Cancer Research Institute established in partnership with the Ludwig Institute for Cancer Research today announced they entered into a collaborative research agreement to support development of Tolerx's drug candidate, TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.
AtheroMed, a developer of innovative technologies for treating peripheral artery disease, announced that it has completed patient enrollment in the EASE clinical study. The EASE study results will be presented by Dr. Stephen Williams, Director, Vascular Medicine Center at Johns Hopkins University, during a Late Breaking Clinical Trials Session on Wednesday, October 9th, at the Vascular Interventional Advances conference in Las Vegas.
Children who are exposed to polychlorinated biphenyls (PCBs), which were commonly used in a range of industrial products, could be at risk of an increase in asthma symptoms, according to new research.
› Verified 3 days ago
Lindsay Mandel Foley, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 7101 Fairway Dr, Palm Beach Gardens, FL 33418 Phone: 561-355-8974 Fax: 561-355-8600 | |
Luis J. Haddock, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7101 Fairway Dr, Palm Beach Gardens, FL 33418 Phone: 561-515-1500 | |
Dr. Michael Ralph Grimmett, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3385 Burns Rd, Suite 209, Palm Beach Gardens, FL 33410 Phone: 561-691-3937 Fax: 561-691-3992 | |
Melanie Reyes Sobel, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 7101 Fairway Dr, Palm Beach Gardens, FL 33418 Phone: 561-515-1500 | |
Nathan Wayne Blessing, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7101 Fairway Dr, Palm Beach Gardens, FL 33418 Phone: 561-355-8663 Fax: 561-355-8618 | |
Dr. Jorge Fortun, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7101 Fairway Dr, Palm Beach Gardens, FL 33418 Phone: 561-515-1500 Fax: 561-515-1513 | |
Oriel Spierer, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 7101 Fairway Dr, Bascom Palmer Eye Institute, Palm Beach Gardens, FL 33418 Phone: 561-515-1500 |